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HIV-associated Kaposi’s sarcoma (KS) is a public health challenge in sub-Saharan Africa since both the causative agent, Kapo-
si’s sarcoma associated-herpesvirus (KSHV), and the major risk factor, HIV, are prevalent. In a nested case-control study
within a long-standing clinical cohort in rural Uganda, we used stored sera to examine the evolution of antibody titres against
the KSHV antigens K8.1 and latency-associated nuclear antigen (LANA) among 30 HIV-infected subjects who subsequently
developed HIV-related KS (cases) and among 108 matched HIV/KSHV coinfected controls who did not develop KS. Throughout
the 6 years prior to diagnosis, antibody titres to K8.1 and LANA were significantly higher among cases than controls
(p< 0.0001), and titres increased prior to diagnosis in the cases. K8.1 titres differed more between KS cases and controls,
compared to LANA titres. These differences in titre between cases and controls suggest a role for lytic viral replication in the
pathogenesis of HIV-related KS in this setting.
Kaposi’s sarcoma (KS) is currently the most commonly
reported cancer in Uganda and in other parts of sub-Saharan
Africa1 where both the underlying cause, Kaposi’s sarcoma
associated-herpesvirus (KSHV), and a key risk factor, HIV,
are prevalent. Well-established assays to diagnose KSHV
infection rely on the detection of antibody responses to
KSHV-speciﬁc antigenic proteins, which are preferentially
expressed during viral latency or lytic replication. The major
protein markers of KSHV latency and lytic replication are
encoded by latency-associated nuclear antigen (LANA) and
K8.1, respectively.2 In case-control studies from South Africa
and Uganda, high antibody titres against KSHV have been
observed in patients with KS compared to controls.3,4 Longi-
tudinal studies in North America and Northern Europe
report that elevated antibody titres against KSHV antigens
LANA and/or K8.1 are present prior to the onset of clinically
evident KS.5–8 However, there are no longitudinal studies
describing the evolution of antibodies against KSHV prior to
the development of KS from the African continent, despite
both virus and tumor being relatively frequent there. The epi-
demiology of KSHV and KS differ between sub-Saharan
Africa and the US and Europe. In Uganda for example,
KSHV infection can be acquired during childhood,9 many
years prior to HIV infection, and estimates of the seropreva-
lence of KSHV range between 36% and 60%.9–13 In contrast,
in the US and Northern Europe, the estimates of KSHV
prevalence are in general lower (<10%),14,15 and infection
with both KSHV and HIV often occurs during adult life.16
These differences may impact on the development of anti-
body responses to KSHV and on the pathogenesis of KS.
Among individuals with HIV-associated KS in sub-
Saharan Africa survival is generally poor.17,18 The limited
prognosis of these individuals can be explained in part by
lack of access to early diagnosis of both HIV and KS and in
part by limited treatment options. The introduction of antire-
troviral therapy (ART) in the US and Europe has been asso-
ciated with a substantial decrease in both the incidence and
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severity of newly diagnosed KS in HIV-infected patients.19,20
However, access to ART remains limited in Uganda; in 2011,
ART coverage for people with advanced HIV infection was
about 50%.21 Therefore, especially in resource limited settings,
identifying those at greatest risk of HIV-associated KS may be
useful for the development of both therapeutic and preventa-
tive strategies to address this important public health concern.
To further our understanding of the patterns of antibody
responses to KSHV over time, we conducted a case-control
study nested within an actively followed population-based
clinical cohort of HIV-infected adults living in rural
Uganda.22–24 We investigated whether the pattern of KSHV
antibody titres over time in individuals who subsequently
develop KS differs from the KSHV antibody titre pattern
among those who do not develop KS.
Material and Methods
Study population
Our study was nested within an actively followed longitudinal
clinical cohort of HIV-infected adults. These individuals were
identiﬁed from within a larger general population cohort
(GPC), established in 1989 in rural South West Uganda, to
study the population dynamics of HIV disease in a typical
rural Ugandan community.25,26
HIV-infected adults identiﬁed within the GPC were invited
to join the Rural Clinical Cohort (RCC)22–24 at diagnosis and
were reviewed in the study clinic at three-monthly intervals.
A clinical questionnaire was completed at each visit and a full
physical examination carried out and documented. ART,
available from 2004, was commenced in accordance with
Ugandan Ministry of Health criteria27: CD4 count of 200 cells
per lL or below; or WHO clinical stage 4; or advanced WHO
clinical stage 3 with persistent or recurrent oral thrush and
invasive bacterial infections; or CD4 count of 250 cells per lL
or below during pregnancy. The ﬁrst-line ART regime was
zidovudine (AZT), lamivudine (3TC) and nevirapine (NVP).
CD4 cell counts were measured (FACSCount, Becton Dickin-
son, San Jose, CA) at baseline, and at every clinic visit a
serum sample was collected and stored at 280C at Medical
Research Council/Uganda Virus Research Institute (MRC/
UVRI) Clinical Diagnostic Laboratory in Entebbe, Uganda.
Patients on ART had an HIV viral load measurement (Ampli-
cor MONITOR 1.5, Roche Molecular Systems, NJ) at drug
commencement and approximately every 6 months thereafter.
We identiﬁed, through the RCC study database, 30 individ-
uals diagnosed with HIV-associated KS, between 2 October
1990 and 5 July 2010. All cases were conﬁrmed by a review of
clinic notes conducted independently by two clinicians. Five
cases had histological veriﬁcation of diagnosis, and the remain-
der had clinical documentation only. Controls were selected
from among HIV-seropositive adults without a diagnosis of
KS during the study period using the following procedure:
each case was classiﬁed by sex, age band ( median age of 37
years or 38 years) and CD4 count band (200 cells per lL,
201–500 cells per lL, 501 cells per lL) at the time of their
KS diagnosis. Potential controls were then examined to ﬁnd
the time points at which their characteristics (sex, age band
and CD4 count band) matched those of the case, and this
time point was then taken as the pseudodiagnosis date for that
control, which for simplicity will be referred to as the KS diag-
nosis date hereafter. Next, to ensure that all controls were
KSHV seropositive at KS diagnosis, those fulﬁlling matching
criteria were tested for KSHV antibodies using the methods
described below, and 149 were found to be KSHV seropositive
to either K8.1 or LANA at KS pseudodiagnosis. For each case,
up to four individually matched controls were selected from
the pool of 149 HIV and KSHV seropositive people, and they
were included in the dataset as matched to the corresponding
case. Results for HIV viral load were considered a suitable rep-
resentation of an individual’s viral load at KS diagnosis if
measured within 100 days.
Laboratory procedures
All available serum samples taken up to and including the KS
diagnosis sample were tested for antibodies against KSHV using
a quantitative lytic K8.1 ELISA and latent LANA ELISA as pre-
viously described.2,28 Serum samples positive for antibodies
against K8.1 at a 1:20 dilution were subsequently tested at dou-
bling dilutions from 1:20 to 1:20,480 to measure titre. Serum
samples positive for antibodies to LANA at a 1:100 dilution
were tested at doubling dilutions from 1:100 to 1:102,400. The
titre value was the dilution before which the sample lost positive
signal. For analysis, the titre values were replaced by a digit rep-
resenting the number of dilutions, from zero for a KSHV sero-
negative sample up to 10 for K8.1 and up to 11 for LANA.
Individuals blinded to patient details performed the KSHV
ELISA assays at the UVRI and at the Viral Oncology Section,
Frederick National Laboratory for Cancer Research.
Statistical analysis
The characteristics of cases and of controls were initially
compared using a Mann–Whitney test, t-test or v2 test as
What’s new?
Infection with Kaposi sarcoma associated-herpesvirus (KSHV) and HIV, the major risk factor for Kaposi sarcoma, is common in
sub-Saharan Africa. However, little is known about the evolution of KSHV antibody responses in HIV-infected individuals prior
to the clinical onset of KS. This study shows that antibody titres against KSHV antigens K8.1 and latency-associated nuclear
antigen (LANA) increase significantly in the six years leading up to HIV-associated KS. Titres of K8.1, a lytic antigen, rose
more than LANA titres, indicating that the activation of genes in the lytic cycle of viral replication is important in KS
development.
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appropriate. The change in titres (deﬁned as the number of
doubling dilutions) prior to KS diagnosis were analyzed using
linear regression adjusted for matching factors age, sex and
CD4 count. Correlation between repeated measurements on
individual patients was adjusted for using generalized esti-
mating equations (GEE) with an exchangeable correlation
structure. To graphically present trends in titre, the GEE
model was used to predict mean titres for cases and controls
from a population of HIV-positive individuals in a 1:1 sex
ratio, with a median age of 37 years and a CD4 count of
between 200 and 500 cells per ml at KS diagnosis. Variability
between individual patients was explored by constructing a
multilevel mixed effects regression model incorporating ran-
dom elements for both the titre level, the trend over time
and covariance between the two. Random effects from the
mixed models for each individual were estimated using the
best linear unbiased predictor. Interactions between time
prior to KS diagnosis and case-control status were examined
in both models to assess whether patterns in titre over time
differed between cases and controls. Tests for statistical
Figure 1. Distribution of titres of antibodies to K8.1 (A) and LANA (8), and doubling dilution equivalents, is 30 HIV-positive individuals with
Kaposi’s sarcoma (KS) and 108 matched controls, at time of diagnosis (for cases) of pseudo-diagnosis (for controls). For each patient with
KS, up to four controls without KS were selected matched for sex, CD4 count group and age. The median titre in each group is indicated by
a horizontal red line. Scatter plot of K8.1 versus LANA titre (C) with linear fits plotted separately for the cases and controls.
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signiﬁcance were derived from likelihood ratio test statistics.
All p values were two-sided, and signiﬁcance was considered
at the 5% level. Analyses were carried out using Stata 12SE
(StataCorp LP, College Station, TX).
Ethical approval
Ethical approval for our study was obtained from the UVRI
Science and Ethics Committee and from the Uganda National
Council for Science and Technology.
Results
Results were available for 30 cases and 108 matched controls.
The median number of samples available from each individ-
ual was 3 (range 1–12). All cases at diagnosis and controls at
pseudodiagnosis were seropositive to either K8.1 or to LANA
but not necessarily to both. At the time of KS diagnosis 93%
(28/30) of the cases were seropositive to K8.1 compared to
69% (74/108) of the controls (p5 0.006). Titres to K8.1 were
higher among KS cases than controls at KS diagnosis (2,640
[interquartile range (IQR) 660–10,240] vs. 40 [IQR 0–80],
p< 0.0001, Fig. 1, Table 1). Similar, but less marked differen-
ces in seroprevalence (p5 0.045) and titre (3,200 [IQR 200–
102,400] vs. 800 [IQR 0–25,600], p< 0.0001) were observed
for the LANA antigen at the KS diagnosis time point: 100%
(30/30) of cases were seropositive compared to 88% (95/108)
of the controls (Fig. 1, Table 1). There was signiﬁcant posi-
tive correlation between K8.1 and LANA titres at KS diagno-
sis among both cases (p5 0.50, p< 0.02) and controls
(p5 0.48, p< 0.0001, Fig. 1c).
There was a signiﬁcant interaction for K8.1 antibody titres
between case-control status and time, such that the difference
in K8.1 titres between cases and controls was largest at the
time points closest to KS diagnosis (Table 2). Estimates from
GEE and random effects models were similar for all parame-
ters (Table 2). Citing the GEE model results: at the time of
diagnosis, K8.1 titres were approximately 16-fold higher
among patients developing KS (4.1 doubling dilutions, 95%
CI: 3.39–4.88) than controls. There was no signiﬁcant time
trend in titres among the control patients (0.02 doubling
dilutions per year, 95% CI: 20.10–0.15); however, titres
among KS patients increased approximately twofold every 2
years (0.48 doubling dilutions per year, 95% CI: 0.23–0.73)
(Table 2, Fig. 2a).
From the random effects model, predicted individual K8.1
antibody dynamics were clearly different for KS cases and
controls (Fig. 2b). Intercept estimates ranged from 3.0 to 8.4
dilutions among people with KS and were lower among con-
trols (range 0.7–7.4 dilutions), with similar variance estimates
within the two groups (Fig. 2c). While there was substantial
overlap in distributions the shapes of the distributions were
different. The slope estimates had no overlap between KS
cases and controls: case K8.1 titres increased at rates between
0.44 and 0.67 dilutions per year whereas rates of change
among controls ranged from a decrease of 20.19 dilutions
Table 1. Characteristics of KS patients at diagnosis and control patients at pseudo-diagnosis
Factor
Case Control
p valuen530 n5108
Sex, n (%)
Female 14 (47%) 52 (48%) Matching factor
Male 16 (53%) 56 (52%)
Age, n (%)
Less that 37 years 14 (47%) 56 (52%) Matching factor
Older than 37 years 16 (53%) 52 (48%)
CD4 count class, n (%)
Less than 200 16 (53%) 60 (56%)
200–500 8 (27%) 24(22%) Matching factor
Greater than 500 6 (20%) 24 (22%)
Median CD4 count at diagnosis, (IQR) 131 (40–468) 177 (109–491) 0.09
On ART at time of diagnosis, n (%) 7 (23%) 21 (19%) 0.61
Comparison of K8.1 results between cases and controls
Median K8.1 titre at diagnosis (IQR) 2640 (660–10,240) 40 (0–80) <0.0001
Median K8.1 titre of all samples (IQR) 320 (80–2,560) 40 (0–80) <0.0001
Comparison of LANA results between cases and controls
Median LANA titre at diagnosis (IQR) 3200 (200–102400) 800 (0–25,600) <0.0001
Median LANA titre of all samples (IQR) 3200 (100–102,400) 800 (0–12,800) <0.0001
p value calculated using Ranksum test, unless otherwise stated
1v2 test
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per year to an increase of 0.14 dilutions per year (Fig. 2d).
Thus, groups were easily distinguished based on slope. Vari-
ability in slope estimates among cases was similar to the var-
iance among controls. There was a small negative covariance
for K8.1 between the intercept (antibody titre at diagnosis)
and slope (rate of change in antibody level) but this did not
contribute signiﬁcantly to the model ﬁt.
The two LANA models were also comparable. From the
GEE model, patients with KS had LANA titres approximately
ﬁve times higher (2.29 doubling dilutions; 95% CI: 1.10–3.48)
than patients who did not have KS; however, there was no
trend in the titres over time and there was no signiﬁcant
interaction between the effects of KS status and time (Table
2, Fig. 3a). Predicted individual LANA titre dynamics of
cases and controls were comparable (Fig. 3b). Distributions
of patient intercepts and slopes overlapped substantially;
intercepts ranged from 1.00 to 10.81 dilutions among KS
cases and from 0.11 to 9.92 dilutions among controls
(Fig. 3c); rates of change in LANA titre (slope) ranged
between 21.29 and 1.77 dilutions per year among individuals
with KS and 20.60 and 1.26 dilutions per year among con-
trols (Fig. 3d). There was a positive covariance for LANA
between intercepts and slopes indicating that individuals with
higher titres at diagnosis had higher rates of change of anti-
body level over time (Fig. 3b).
Given the infrequent use of ART (Table 1) and conse-
quently the few viral load measurements available, adjusting
for ART status and HIV viral load at time of KS diagnosis
did not materially change the results of any of the models
(data not shown).
Discussion
This is the ﬁrst longitudinal study examining patterns of
antibody titres to both K8.1 and LANA in individuals with
HIV-associated KS, living in a KSHV-endemic population in
sub-Saharan Africa. The study has shown that individuals
Figure 2. K8.1 titres in the six years prior to diagnosis (for cases) or pseudo-diagnosis (for controls). (A) for Kaposi’s sarcoma (KS) cases
(red symbols and lines) and non-KS controls (blue symbols and lines) with predictions bases on the GEE (A) and random effects (B) regres-
sion models presented in Table 2. GEE regression model predictions are based on a group of patients in a 1:1 sex ratio, at the median of
37 years at diagnosis and with a C04 count between 200 and 500 cells/ml; the shaded areas represent the 95% confidence intervals. Ran-
dom effects model predictions are the fitted lines for each individual patient with at least 2 measurements. Distributions of individual inter-
cept (C) and slope (D) estimates from the random effect model. Red bars/boxes denote KS cases and blue bars/boxes denote control
patients. In
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who develop HIV-associated KS have higher K8.1 and LANA
antibody titres compared to those who do not, and that this
is evident up to 6 years prior to KS diagnosis. In addition,
K8.1 antibody titre increased with time toward KS diagnosis
among cases, whereas individuals who did not develop KS
had relatively stable titres over time.
The results presented here are in accord with studies con-
ducted among cohorts based in the West; antibody titres
against KSHV antigens are higher among cases and increase
prior to tumor diagnosis.5,6,8,16,29 Prospective studies meas-
uring both lytic and LANA KSHV antibodies by ELISA are
lacking. However, one study of HIV-infected people in the
United Kingdom reported an increased risk of KS with
increasing LANA antibodies measured by ELISA.6
Like all herpesviruses, KSHV cycles between two distinct
phases: latency, a quiescent state of persistent infection essen-
tial for the development of KS, and lytic reactivation, charac-
terized by ordered increased gene transcription and in most
cases, viral replication and host cell death.30 In KS lesions,
most infected cells are latently infected and express only the
latency-associated genes including the antigen encoded by
LANA.31 However, a small population of cells (<5%) also
express lytic antigens including K8.1, indicating that lytic
gene expression has a role in KS carcinogenesis.32 Many of
the genes implicated in oncogenesis such as vGPCR are
expressed during the lytic cycle. Clinical studies have also
suggested the potential importance of lytic gene activation in
KS development. In a clinical trial treatment with oral or
intravenous ganciclovir, a drug that blocks lytic but not latent
KSHV infection reduced the incidence of KS.33–35
The raised K8.1 titres among individuals who develop
HIV-associated KS found in our study is in accord with the
evidence that lytic gene expression may be important in KS
tumorigenesis. It is likely that cellular immune responses are
also critical to KS risk, as has been shown for transplant-
associated KS.36 Future studies examining the interplay
between KSHV viral load, antibody titre and cellular immune
responses are warranted.
Figure 3. LANA titres in the six years prior to diagnosis (for cases) or pseudo-diagnosis (for controls). (A) for Kaposi’s sarcoma (KS) cases
(red symbols and lines) and non-KS controls (blue symbols and lines) with predictions bases on the GEE (A) and random effects (B) regres-
sion models presented in Table 2. GEE regression model predictions are based on a group of patients in a 1:1 sex ratio, at the median of
37 years at diagnosis and with a C04 count between 200 and 500 cells/ml; the shaded areas represented the 95% confidence intervals.
Random effects model predictions are the fitted lines for each individual patient with at least 2 measurements. Distributions of individual
intercept (C) and slope (D) estimates from the random effect model. Red bars/boxes denote KS cases and blue/boxes denote control
patients.In
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Our study had a number of limitations. The deﬁnition of
case-control status in our study relied, in the majority of cases,
on clinical diagnoses made at the time of a regular clinic visit.
While large dermal KS lesions are relatively easy to diagnose,
lack of histological conﬁrmation may have resulted in some
misclassiﬁcation of cases and controls and small dermal lesions
may have been missed. Further, no diagnostic tests were avail-
able to ensure that controls did not have visceral KS involve-
ment or another KSHV-related pathology. Date of KS diagnosis
was based on the clinical review date, which may have been
affected by how regularly the HIV clinic was attended. Only
simple linear titre dynamics could be investigated in our study
because the majority of patients had only three samples avail-
able. The results of our study also rely on the validity of the
measured antibody titre. The relatively small numbers of indi-
viduals on ART at KS diagnosis, in spite of low CD4 counts,
reﬂects local policy (treatment of individuals with CD4 T-cell
counts below 200 per ml) and limited access to ART in Uganda
at the time when these cases were diagnosed.
In our study, K8.1 titres provided a more useful means
of differentiating patients developing KS from those who
did not, compared to LANA titres. The differences in titre
between cases and controls were sufﬁciently pronounced
that the ﬁndings might have some clinical utility in terms of
predicting which individuals may develop HIV-associated
KS. K8.1 titres showed more marked differences than LANA
titres and the slope of change in K8.1 titres completely dis-
tinguished cases from controls, suggesting that this may be
a particularly useful parameter for such a purpose. In fur-
ther research, development of a simple assay and investiga-
tion as to whether these parameters could be of use in other
patient groups (such as transplant recipients) might be
considered.
For the related gammaherpesvirus, Epstein-Barr virus, age
at infection is known to be an important determinant of out-
come.37 The fact that KSHV titres are higher among cases,
compared to controls, so long prior to diagnosis, might sug-
gest that events early in KSHV infection determine subse-
quent risk of disease; age at infection with KSHV may be
related to this but whether this is a key determinant of
KSHV load is not known. Our results suggest that investiga-
tion of this, and identiﬁcation of risk factors associated with
elevated KSHV load, is relevant to understanding KS risk
and pathogenesis.
In conclusion, during the 6 years prior to KS diagnosis,
antibody titres against KSHV antigens K8.1 and LANA were
signiﬁcantly higher among cases compared to controls and
K8.1 titres increased as diagnosis approached. These ﬁndings
suggest strategies for identifying and understanding KS dis-
ease risk and support the hypothesis that lytic gene expres-
sion and replication are important in the pathogenesis of
HIV-related KS in this setting.
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